Eli Lilly recently disclosed data showing an experimental weight-loss drug drove average weight loss of 28% of body weight among trial participants with obesity -- a marked increase in potency compared with currently available GLP-1 medications such as semaglutide (roughly 15% average loss) and tirzepatide (roughly 20%).
The scale of the results has prompted a wave of physician commentary about the tradeoffs of increasingly potent weight-loss drugs, with some doctors noting that greater average weight loss can come with greater risk of side effects and complications, particularly at the fastest rates of loss.
The results arrive against a broader backdrop of rapid growth in the GLP-1 category. Industry analysts have projected the global incretin drug market could reach roughly $200 billion by 2030, with the number of Americans on GLP-1 treatment potentially reaching 25 to 30 million by that year, up from roughly 10 million in 2025.
Physicians interviewed about the new data have generally cautioned that higher average weight loss isn't automatically better for every patient, and that rate of loss -- not just total amount -- carries its own considerations, echoing longstanding research showing that very rapid weight loss is associated with greater lean muscle loss and more pronounced metabolic adaptation.
For readers evaluating any weight-loss approach, medication-assisted or not, understanding how adaptation and pace affect long-term outcomes remains relevant -- see our article on slow versus fast weight loss.